This is a huge expansion plan into China and SE Asia moving forward on top of the medical cannibis import license (which only 7 entities in Australia have achieved). Moving very fast forwards.
Key for me in this update is that BDA have achieved $300k revenue YTD only for this quarter. So if I extrapolate to the end of this quarter I anticipate revenue to be ~$400k.
If you look at current forecast expenditure for this quarter of $571k. BDA is teethering on cashflow positive which makes BDA a self sustaining entity. I am anticipating cashflow positive over the following two quarters or earlier. 56% profit margin is huge for any product. This plays well to maintaining our capital structure and hopefully much higher prices and valuations.
![]()
Costs are maintained well by the BDA management team.
Then you look at peer market comparison below and one would think BDA has significant upside potential to peer valuation average.
![]()
Looking forward to FY2018.
- Forums
- ASX - By Stock
- BOD
- Ann: Strong growth and expansion of footprint into China
Ann: Strong growth and expansion of footprint into China, page-9
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOD (ASX) to my watchlist
|
|||||
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.256M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
BOD (ASX) Chart |
Day chart unavailable